MCRN Canadian-Designed Clinical Trial Inspires a Global Phase III Trial
April 10, 2017
Inspired by the success of the Phase II MCRN 002 STOMP trial, Karyopharm has turned to MCRN investigators to participate and lead the Phase III global registration trial for selinexor. Only therapies that are effective, safe and have tolerable side effects can proceed to Phase III testing.
The Terry Fox Research Institute Invests $5 Million in Myeloma Research
March 23, 2017
Bringing Game-Changing Therapies to Canadian Patients: Active MCRN Clinical Trials
February 23, 2017
The Myeloma Canada Research Network (MCRN) brings innovative Canadian-designed clinical trials to hundreds of patients in 24 centres in 9 provinces across Canada. Read more for updates on MCRN active clinical trials and a preview of MCRN 004, which will begin recruiting in summer 2017.
First Multiple Myeloma Database for Canada Captures Real-World Patient Evidence
September 1, 2016
A press conference was held yesterday in Toronto to officially launch the Myeloma Canada Research Network National Multiple Myeloma Database. A first of its kind in Canada, "the Database is a key stepping stone to finding a cure" said Dr Reece